| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/03/2022 | 222.58% | Oppenheimer | → $5 | Upgrades | Perform → Outperform |
| 03/10/2022 | 545.16% | Piper Sandler | $12 → $10 | Maintains | Overweight |
| 07/01/2021 | 674.19% | Berenberg | → $12 | Downgrades | Buy → Hold |
| 06/29/2021 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 03/01/2021 | 2222.58% | Oppenheimer | → $36 | Initiates Coverage On | → Outperform |
| 03/01/2021 | 1512.9% | Piper Sandler | → $25 | Initiates Coverage On | → Overweight |
Sensei Biotherapeutics Questions & Answers
The latest price target for Sensei Biotherapeutics (NASDAQ: SNSE) was reported by Oppenheimer on October 3, 2022. The analyst firm set a price target for $5.00 expecting SNSE to rise to within 12 months (a possible 222.58% upside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Sensei Biotherapeutics (NASDAQ: SNSE) was provided by Oppenheimer, and Sensei Biotherapeutics upgraded their outperform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sensei Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sensei Biotherapeutics was filed on October 3, 2022 so you should expect the next rating to be made available sometime around October 3, 2023.
While ratings are subjective and will change, the latest Sensei Biotherapeutics (SNSE) rating was a upgraded with a price target of $0.00 to $5.00. The current price Sensei Biotherapeutics (SNSE) is trading at is $1.55, which is within the analyst's predicted range.